Endocrinology prior authorization at Elevance Health
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Elevance Health endocrinology PA at a glance
Elevance Health reviews endocrinology PA submissions against its medical policy library, with rules drawn primarily from ADA Standards of Care + AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm. Elevance Health-specific context: Operates Anthem BCBS in 14 states. Owns Carelon (formerly AIM) which manages utilization for specialty drugs and advanced imaging. State complaint route is to the state insurance department where the policy was issued.
Documentation packet — what to send
- Diagnosis (T2D vs obesity vs cardio-renal indication) with ICD-10
- BMI + comorbidities
- Most recent A1c
- Prior diabetes therapies with duration and reason for change
- Cardiovascular or renal comorbidity supporting the cardio-renal indication
Common denial patterns to pre-empt
Patterns observed in endocrinology across payers, and where Elevance Health's book of business overlaps:
- Weight-loss exclusion (Wegovy, Zepbound) — coverage limited to diabetes indication
- Step therapy requiring metformin / SU first
- A1c threshold for GLP-1 initiation not met
- BMI threshold above FDA label for anti-obesity indication
- Quantity limit (28 days vs 90-day supply)
- Step therapy
Appeal angles when Elevance Health denies
- ADA Standards of Care year-specific recommendation
- Established CV disease (qualifies for cardio-renal indication)
- Established CKD (SGLT-2i / GLP-1 cardio-renal benefit)
- Functional comorbidity (sleep apnea, OA) supporting AOM coverage
Peer-to-peer prep
- Differentiate diabetes-indication semaglutide (Ozempic) from weight-loss (Wegovy) — common P2P confusion point
- Have the latest A1c, lipid panel, eGFR, and UACR open
- Reference the cardiovascular outcome trial by name (SUSTAIN-6, EMPA-REG, SELECT) when arguing for the cardio-renal indication
- Quote the ADA Standards of Care recommendation grade (A, B, C, E)
Drug-specific PA criteria at Elevance Health
Deep dives on each drug's PA criteria at Elevance Health:
Frequently asked questions
What documentation does Elevance Health need for endocrinology prior authorizations?
Elevance Health's PA packet for endocrinology typically includes: Diagnosis (T2D vs obesity vs cardio-renal indication) with ICD-10; BMI + comorbidities; Most recent A1c; Prior diabetes therapies with duration and reason for change. ADA Standards of Care + AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm citations strengthen the submission.
What's the turnaround at Elevance Health?
Elevance Health standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which endocrinology drugs does Elevance Health most often PA-restrict?
Top targets in endocrinology: semaglutide, tirzepatide, liraglutide, empagliflozin, dapagliflozin. Each follows the per-drug step therapy + documentation requirements published in Elevance Health's medical policy library.
How do I prep a peer-to-peer with Elevance Health in endocrinology?
Differentiate diabetes-indication semaglutide (Ozempic) from weight-loss (Wegovy) — common P2P confusion point Have the latest A1c, lipid panel, eGFR, and UACR open Have the policy URL and the patient's chart open before the call.
Generate a Endocrinology PA packet
Open ApprovalHelp — generate a endocrinology PA packet tailored to Elevance Health's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com